Table 3 Multivariate analysis between cumulative overall survival rates and clinicopathological characteristics of GC patients
From: Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
Variables | HR (95% CI) | P value |
|---|---|---|
Age, > 70 (vs. ≤ 70) | 1.734 (0.650–4.628) | 0.271 |
Gender, female (vs. male) | 1.069 (0.589–1.940) | 0.827 |
Pathological grade, III/IV (vs. I/II) | 1.260 (0.661–2.401) | 0.483 |
Depth of invasion, T3/T4 (vs. T1/T2) | 1.883 (1.135–3.122) | 0.014 |
Lymph node metastases, N1/N2/N3 (vs. N0) | 2.251 (0.809–6.261) | 0.120 |
Distant metastasis, M1 (vs. M0) | 1.480 (0.815–2.687) | 0.198 |
TNM stage, III/IV (vs. I/II) | 2.349 (1.342–4.114) | 0.003 |
XRCC5 expression, high (vs. low) | 1.795 (1.076–2.994) | 0.025 |
CLC-3 expression, high (vs. low) | 1.671 (1.012–2.758) | 0.045 |